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JAAD ONLINE: NOTES &
Food and Drug Administration’s
proposed sunscreen final
administrative order: How does it
affect sunscreens in the United
States?
To the Editor: On September 24, 2021, the US Food
and Drug Administration (FDA) released a proposed
final administrative order for sunscreen drug products.1,2 The release of this proposed order replaces the
2019 Proposed Rule in order to fulfill the statutory
provisions of the Coronavirus Aid, Relief, and
Economic Security Act, signed into law on March 27,
2020. The Coronavirus Aid, Relief, and Economic
Security Act replaced the FDA monograph rulemaking process, which is laborious and time-consuming,
with an administrative order process that should be
more efficient.3 There is a 45-day comment period.
After the FDA addresses all comments, a final administrative order will be issued, which would become
effective no sooner than 1 year after its release.
Once the final order is issued, companies will only
be able to continue marketing sunscreens with a
given active ingredient if the FDA has determined the
active ingredient is generally recognized as safe and
effective (GRASE), unless they first seek FDA
approval. Until then, the FDA does not require
companies to remove products from the market.
Highlights of the proposed order, which is similar
to the FDA Proposed Rule released in February
2019,4 are shown below:
1. GRASE status of approved UV filters:
GRASE: zinc oxide and titanium dioxide;
Not GRASE due to safety issues: paraaminobenzoic acid and trolamine salicylate;
Not GRASE because additional data are needed
(12 ingredients): cinoxate, dioxybenzone,
ensulizole, homosalate, meradimate, octinoxate,
octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, and avobenzone.
Of note, paraaminobenzoic acid and trolamine
salicylate are no longer used in sunscreens marketed
in the US. For the other 12 ingredients with ‘‘not
GRASE’’ status, if data are not available at the end of
the 45-day comment period, the FDA would be
prepared to defer the final decision on the ingredients provided the FDA is satisfied that timely
progress is being made on the necessary studies.
Such a deferral would be for a period of not more
than 1 year, with a possible extension.
At the time of this writing, industry is working
with the FDA on testing requirements for 8 of the 12
ingredients. These 8 are avobenzone, ensulizole,
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homosalate, meradimate, octinoxate, octisalate,
octocrylene, and oxybenzone.
2. Maximum sun protection factor: 601. However, marketing of products with a sun protection
factor of up to 80 would be permissible.
3. Broad spectrum requirements: These would be
required for all products with a sun protection
factor of $15; a proposed new requirement of
a UV-A I/UV ratio of 0.7 or higher would need
to be met.
4. Dosage forms: Oils, lotions, creams, gels, butters,
pastes, ointments, and sticks are proposed to be
GRASE. Sprays, subject to testing and labeling
requirements, are also proposed to be GRASE.
Additional data are needed for powders before a
determination of GRASE status can be made.
5. Labeling: Active ingredients are to be listed
alphabetically on the principal display panel
(ie, the panel visible on the retail shelf).
6. Sunscreen-insect repellent combinations: These
products are proposed to be considered not
GRASE.
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